Source link : https://www.newshealth.biz/health-news/no-new-safety-signals-seen-with-migraine-prevention-drug/
DENVER — No new safety signals emerged with daily atogepant (Qulipta) for migraine prevention, an interim analysis of a long-term safety extension study showed, and improvements in efficacy were sustained. After an average exposure to atogepant of about 500 days, treatment-emergent adverse events occurred in 79% of migraineurs, but most were mild or moderate and […]
Author : News Health
Publish date : 2024-04-16 21:49:12
Copyright for syndicated content belongs to the linked Source.